Fast Facts
Ages 60-80
No diabetes or heart diseases
Compensation
provided
Conducted in
Columbia, MO
Additional Information
The purpose of this clinical trial is to see if a medication called empagliflozin can affect blood vessel health in adults ages 60-80.
You may qualify for this survey if you meet the following criteria:
- Ages 60-80
- BMI < 45
- No heart disease diagnosis
- No diabetes diagnosis
Individuals who identify as a person of color (POC) are encouraged to apply.
If you are eligible and choose to participate in the research study, you will complete:
- A 2-hour screening visit
- Two 30-minute equipment fittings
- Two 2-hour follow-ups
- Two 4-hour assessments
- 12 weeks of home medication/placebo administration
All study visits will occur at the University of Missouri’s Clinical Translational Science Unit (CTSU).
You will receive up to $600 in compensation for your participation in the study.
There is no cost for you to participate in our research study.